Ireland is winning manufacturing investment at a rate few countries can match. Pharma companies keep expanding existing sites, medtech firms keep picking Irish locations for new European plants, and automotive and composites suppliers are following the same path for many of the same reasons. What gets less coverage is the strain that investment is putting on the workforce that has to actually build and commission these lines. Ireland doesn't have an investment problem. It has a people problem, and it's worth understanding both halves before you commit a project there.
Why Manufacturers Keep Choosing Ireland
The fundamentals haven't changed. Ireland's standard corporate tax rate of 12.5% (15% for large multinationals under the OECD's Pillar Two rules since 2024) sits well below the EU average of around 21.5%, and more importantly it's barely moved since the mid-1990s. For a finance director signing off a nine-figure capital project, that predictability matters more than a marginally lower rate somewhere else that could change with the next election.
EU single market membership adds a second, less-discussed advantage: assembled and semi-finished parts made in Ireland move across all 27 member states with no customs friction. For a component manufacturer supplying several European vehicle or aerospace assembly lines, that frictionless import and export of assembled parts is often as decisive as the tax position. On top of that, Ireland's regulatory track record, backed by more than 90 FDA-approved plants and a long, well-understood inspection history, shortens the path from qualification to full production for anyone manufacturing a regulated product.
Not Just Pharma: Automotive and Life Sciences Too
Ireland's motor vehicle parts and accessories manufacturing sector is on track for around €721 million in revenue this year, with steady growth driven by demand for the advanced components going into modern vehicles. Alongside it, Ireland's broader life sciences base, medtech as well as pharma, has kept deepening: 14 of the world's top 15 medical technology companies now have an Irish presence, Boston Scientific has been there since 1994, Abbott for over 70 years, and Medtronic for more than 40. Dexcom's decision to put its first European manufacturing site in Athenry, a €300m-plus investment expected to bring around 1,000 jobs, is a recent example of that pull still working. Automotive and life sciences manufacturers are choosing Ireland for the same reasons pharma always has: tax certainty, frictionless EU trade, and a regulatory and quality culture that supply chains trust.
The Shortage Behind the Boom
Here's the part that doesn't make the investment announcements: Ireland is attracting capital faster than it can produce the engineers to turn it into working production capacity. Engineers Ireland is projecting a shortfall of more than 20,000 engineers over the next decade, and a 2025 ManpowerGroup survey found 76% of Irish employers already struggling to fill roles, among the highest rates in Europe. Competition is sharpest in exactly the disciplines a new manufacturing line depends on: maintenance, automation, design and process engineering.
Limerick's electronics cluster is a useful example of what this looks like in practice. Analog Devices is midway through a roughly €100 million wafer fabrication expansion at Raheen, Dell Technologies has pivoted its largest non-US campus toward engineering validation and hardware testing, and IDA Ireland is zoning further advanced manufacturing capacity on the city's edge. The capital is moving. Senior validation and automation engineer roles in that same cluster are sitting unfilled for 90 to 120 days.
The money is moving. The people are not.
| Indicator | Figure |
|---|---|
| Engineers Ireland projected shortfall, next 10 years | 20,000+ |
| Irish employers reporting difficulty filling roles | 76% |
| Time to fill senior automation/validation roles, Limerick cluster | 90–120 days |
| New engineering employment permits issued to overseas hires (2024) | 1,300+ |
What the Shortage Means If You're Building There
None of this makes Ireland a bad choice. The underlying case is still strong. But it changes how a project needs to be planned. Local automation and controls talent is competing with pharma, medtech, semiconductor and automotive employers all drawing from the same pool, which pushes up salaries and stretches recruitment timelines well beyond what a UK-based project would budget for. Waiting until the building is up to start looking for a controls partner is the single most common way projects lose months they didn't plan to lose.
How Duke Can Help
Duke isn't based in Ireland, but the connection isn't cold either: one of our directors calls the country home, and we already work as flexible engineering resource on projects that need PLC programming, robot integration, electrical design and virtual commissioning, without adding to the demand on Ireland's own stretched talent pool. Virtual commissioning in particular lets us prove a cell digitally before a single engineer needs to be on site, which matters most exactly where local capacity is tightest.
Get in Touch →What This Means for Your Project
If you're specifying a new line in Ireland, start the automation conversation at the same time as the site selection conversation, not after it. Budget for realistic recruitment timelines rather than the ones you'd expect at home, and look beyond the local market early if the sectors you're competing with for talent (pharma, medtech, semiconductors, automotive) are already stretching it thin. Ireland's fundamentals haven't changed. What's changed is that getting the automation side right now takes more planning than it used to.